Bioverativ Inc Stock

Stocks

18-04-27	Sanofi : sees new acquisitions and drugs reviving growth	RE
18-03-29	Takeda Pharmaceutical : Merits of any Takeda bid for Shire questioned, shares slide	RE
18-03-29	Takeda Pharmaceutical : Merits of any Takeda bid for Shire questioned, shares slide	RE
18-03-28	Takeda Pharmaceutical : Drugmaker Shire soars as Japan's Takeda considers bid	RE
18-02-15	Bioverativ : Oxford BioMedica wins second $100 million gene therapy contract	RE
18-02-07	Ablynx : Sanofi's return to profit growth this year slower than hoped	RE
18-01-29	Ablynx : Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom	RE
18-01-22	Stocks hit record as senators reach deal to end shutdown	RE
18-01-22	Compagnie Financiere Richemont : Dealmaking drives European stocks as equity melt-up continues	RE
18-01-22	Ablynx : Biotech M&A takes off as Sanofi and Celgene spend $20 billion	RE
18-01-22	Biogen : Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion	RE
18-01-22	Bioverativ : New drugs recast $10 billion haemophilia market as Sanofi swoops in	RE
18-01-22	Biogen : Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion	RE

18-03-06	Bioverativ : Announces First Patient Dosed in Phase 3 Study of BIVV009 for Treatment of Cold Agglutinin Disease	BU
18-02-14	Bioverativ : Haemophilia Publishes a Retrospective Analysis Investigating the Use of ELOCTATE® for Immune Tolerance Induction in People with Inhibitors and Severe Hemophilia A	BU
18-02-13	Bioverativ : Reports Fourth Quarter and Full Year 2017 Performance	BU
18-01-24	The Law Offices of Vincent Wong : Notifies Investors of an Investigation of Bioverativ Inc. in Connection with the Sale of the Company to Sanofi	BU
18-01-24	WeissLaw LLP : Investigates Bioverativ Inc. Acquisition	PR

18-03-28	Sanofi : L'offre publique d'achat de Sanofi sur Ablynx débutera le 4 avril
18-03-08	Sanofi finalise l'acquisition de Bioverativ
18-03-08	Bioverativ : Sanofi finalise l'acquisition de Bioverativ, qui quitte la Bourse
18-02-23	Sanofi : franchit une étape dans son offre sur Bioverativ
18-02-07	Sanofi: Amélioration attendue en 2018 plus lente que prévu

Manager	Title	Age	Since
Brian Foard PSD	President	-	-
Timothy Harris PRN	Corporate Officer/Principal	76	2017-01-31
Joann Nestor SEC	Corporate Secretary	-	-

Director	Title	Age	Since
Philippe Sauvage BRD	Director/Board Member	49	2018-03-07
Brian Foard BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOVERATIV INC	-.--%	+0.30%	-	-	0
ARGENX SE	-2.19%	+6.01%	+66.90%	+123.30%	56.21B
WUXI APPTEC CO., LTD.	+0.55%	+8.49%	+77.09%	+100.93%	55.38B
BIONTECH SE	+0.93%	+4.11%	-12.64%	-12.98%	23.75B
INSMED INCORPORATED	+0.36%	+3.42%	+9.61%	+407.11%	23.19B
WUXI BIOLOGICS (CAYMAN) INC.	+3.18%	+7.67%	+38.95%	-6.46%	18.14B
GENMAB A/S	+0.28%	+5.51%	+36.93%	-30.23%	16.84B
PHARMAESSENTIA CORPORATION	+1.49%	+17.24%	+174.91%	+344.55%	15.86B
EXELIXIS, INC.	-0.83%	+2.06%	+23.70%	+182.37%	13.56B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+6.19%	+12.07%	+40.55%	-	12.97B
Average	+0.96%	+6.94%	+50.67%	+138.57%	26.21B
Weighted average by Cap.	+0.37%	+6.60%	+54.69%	+129.92%

Employees

Sector